Name
Binimetinib
Alternate Names
MEKTOVI
MEK162
Abbreviations
None
Category
Chemotherapy
Subcategory
MEK 1/2 Inhibitor
NSC Number
None
Primary Site
None
Histology
Melanoma
Remarks
June 27, 2018: FDA approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Coding
This drug should be coded